Wednesday, 19 December 2012

Flu is transmitted before symptoms appear, study in ferrets suggests

Aug. 29, 2012 — Research at Imperial College London examining influenza transmission in ferrets suggests that the virus can be passed on before the appearance of symptoms. If the finding applies to humans, it means that people pass on flu to others before they know they're infected, making it very difficult to contain epidemics.

The research was supported by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre.

Knowing if people are infectious before they have symptoms is important to help authorities plan for an epidemic, but is has been difficult to establish this from data collected during outbreaks. Previous research using mathematical models estimated that most flu transmission occurs after the onset of symptoms, but some happens earlier.

The new study, published in the open access journal PLoS ONE, is the first to investigate this question experimentally in an animal model. Ferrets are commonly used in flu research because they are susceptible to the same virus strains and show similar symptoms to humans.

Ferrets with flu were put in contact with uninfected ferrets for short periods at different stages after infection. Transmission occurred before the first symptom, fever, appeared, both when the ferrets were in the same cage and when they were in adjacent cages.

Professor Wendy Barclay, the study's lead author from the Department of Medicine at Imperial College London, said: "This result has important implications for pandemic planning strategies. It means that the spread of flu is very difficult to control, even with self-diagnosis and measures such as temperature screens at airports. It also means that doctors and nurses who don't get the flu jab are putting their patients at risk because they might pass on an infection when they don't know they're infected."

The flu strain used in the study was from the 2009 swine flu pandemic, which killed almost 300,000 people worldwide.

The researchers found that ferrets were able to pass on flu to others just 24 hours after becoming infected themselves. The animals did not suffer from fever until 45 hours after infection and began sneezing after 48 hours. The results are consistent with earlier studies which found that sneezing is not necessary to transmit flu -- droplets of virus are expelled into the air during normal breathing.

In the late stages of infection, after five or six days, flu was transmitted much less frequently, suggesting that people can return to work or school soon after symptoms subside with little risk of passing flu on to others.

The first author, Dr Kim Roberts, who is now based at Trinity College Dublin, said: "Ferrets are the best model available for studying flu transmission, but we have to be cautious about interpreting the results in humans. We only used a small number of animals in the study, so we can't say what proportion of transmission happens before symptoms occur. It probably varies depending on the flu strain."

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by Imperial College London, via AlphaGalileo.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

Kim L. Roberts, Holly Shelton, Peter Stilwell, Wendy S. Barclay. Transmission of a 2009 H1N1 Pandemic Influenza Virus Occurs before Fever Is Detected, in the Ferret Model. PLoS ONE, 2012; 7 (8): e43303 DOI: 10.1371/journal.pone.0043303

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

Reconstructed 1918 influenza virus has yielded key insights, scientists say

Sep. 11, 2012 — The genetic sequencing and reconstruction of the 1918 influenza virus that killed 50 million people worldwide have advanced scientists' understanding of influenza biology and yielded important information on how to prevent and control future pandemics, according to a new commentary by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and several other institutions.

By sequencing the 1918 virus, researchers were able to confirm that the viruses that caused influenza pandemics in 1957, 1968, and 2009 were all descended in part from the 1918 virus. Studies showed that the 2009 pandemic virus had structural similarities with the 1918 virus and explained why younger people, who had never been exposed to the 1918 virus or its early descendants, were most vulnerable to infection by the 2009 influenza virus. As a result, public health officials were able to target limited vaccine supplies to predominantly younger people, who needed vaccine protection most, rather than the elderly, who were at lower risk of infection in 2009, but are traditionally the most important target group for vaccination.

Further, determining the physical structure of parts of the 1918 virus, particularly the portions that are consistent across influenza viruses, has informed the ongoing development of candidate "universal" influenza vaccines that may be given infrequently yet protect broadly against multiple influenza viruses. In addition, by comparing the 1918 virus to related influenza viruses found in animals, scientists have learned some of the changes necessary for influenza viruses to adapt from an animal to a human host. This has led to more targeted surveillance of certain influenza viruses in animals that may be more likely to move to humans.

More generally, the authors say that reconstruction of the 1918 influenza virus has furthered scientific understanding of how novel influenza viruses emerge and evolve. Additionally, study of the 1918 influenza virus has helped clarify the critical effects of the human immune system's response to viral infection and the importance of bacterial co-infections that often follow the influenza infection. In sum, the authors write, learning more about the 1918 pandemic influenza virus has led to important insights that could help prevent or mitigate seasonal and pandemic influenza.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by NIH/National Institute of Allergy and Infectious Diseases, via EurekAlert!, a service of AAAS.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

JK Taubenberger et al. Reconstruction of the 1918 influenza virus: Unexpected rewards from the past. mBio, 2012 (in press) DOI: 10.1128/mBio.00201-12

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

Mandatory flu vaccine for health care workers to protect patients

Oct. 29, 2012 — All health care workers in health care institutions should be vaccinated with the annual influenza vaccine to protect patients, argues an editorial in CMAJ (Canadian Medical Association Journal).

"Each season, 20% of health care workers get influenza, and 28% of young healthy adults who get it have asymptomatic or subclinical infections," writes Dr. Ken Flegel, Senior Associate Editor, CMAJ. "Some of them may shed virus up to a day before symptoms appear. It is time that all people who work in a health care institution be vaccinated."

In Canada, there are approximately 20 000 hospital admissions related to influenza and an estimated 4000 to 8000 deaths attributed to the illness. However, 55%螭% of physicians do not get vaccinated against the flu and are putting patients at risk of illness and death.

Dr. Flegel argues that flu vaccination for health workers must be compulsory, although there could be exemptions for medical or religious reasons. A vaccination rate above 90% is required to prevent outbreaks in hospitals. Mandatory programs for health care workers in many US institutions have resulted in participation rates of about 95%.

"Our schools have shown us the way. During measles outbreaks, access to schools has been successfully denied to nonvaccinated children and staff. The time has come for health care institutions to demand that all health care workers be vaccinated. Our patients' lives depend on this change," Dr. Flegel concludes.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by Canadian Medical Association Journal, via EurekAlert!, a service of AAAS.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

Avian flu viruses which are transmissible between humans could evolve in nature

June 21, 2012 — It might be possible for human-to-human airborne transmissible avian H5N1 influenza viruses to evolve in nature, new research has found.

The findings, from research led by Professor Derek Smith and Dr Colin Russell at the University of Cambridge, were published June 22 in the journal Science.

Currently, avian H5N1 influenza, also known as bird flu, can be transmitted from birds to humans, but not (or only very rarely) from human to human. However, two recent papers by Herfst, Fouchier and colleagues in Science and Imai, Kawaoka and colleagues in Nature reveal that potentially with as few as five mutations (amino acid substitutions), or four mutations plus reassortment, avian H5N1 can become airborne transmissible between mammals, and thus potentially among humans. However, until now, it was not known whether these mutations might evolve in nature.

The Cambridge researchers first analysed all of the surveillance data available on avian H5N1 influenza viruses from the last 15 years, focusing on birds and humans. They discovered that two of the five mutations seen in the experimental viruses (from the Fouchier and Kawaoka labs) had occurred in numerous existing avian flu strains. Additionally, they found that a number of the viruses had both of the mutations.

Colin Russell, Royal Society University Research Fellow at the University of Cambridge, said: "Viruses that have two of these mutations are already common in birds, meaning that there are viruses that might have to acquire only three additional mutations in a human to become airborne transmissible. The next key question is 'is three a lot, or a little?' "

The scientists explored this key question using a mathematical model of how viruses replicate and evolve within a mammalian host and assessed the influence of various factors on whether the remaining three mutations could evolve in a single host or in a short chain of transmission between hosts

The factors that increased the likelihood of mutations evolving are:

1. Random mutation. The replication mechanisms of influenza viruses don't make perfect copies. On average, every time an influenza virus replicates itself it makes approximately one mutation somewhere in the genome of each new virus. In each infected human there will be billions of viruses, and thus with many viruses replicating, multiple mutations can accumulate within a single host.

2. Positive selection. If some of the remaining mutations help the avian virus to adapt to mammals, then those mutations will make the viruses more fit and thus will be positively selected and preferentially accumulate.

3. Long infection. The longer someone is infected and producing new viruses, the more time there is for mutations to accumulate.

4. Functionally equivalent substitutions. The sets of substitutions identified by Fouchier and Kawaoka are unlikely to be the only combinations of substitutions capable of producing an aerosol transmissible virus. The probability of emergence increases with the number of combinations.

5. Diversity in the within-bird virus population. Given all of the mutations there are likely to be within a host due to random mutation, it is possible that the viruses from a bird that infect a human might have a mutation that would not be detected by routine surveillance. For example, if 100 virus particles from a bird infect a human and one of those particles had a key mutation, it would increase the probability of the mutation reaching high levels within a host even though routine sequencing would not detect it.

6. Transmission between mammals. If mammals are capable of transmitting viruses that have some but not all of the necessary substitutions it could increase the probability of an airborne transmissible virus evolving.

The factors that decreased the likelihood of mutations evolving are:

1. An effective immune response. An effective immune response would shorten the length of an infection and thus decrease the time available to accumulate mutations.

2. Deleterious substitutions. If any of the substitutions necessary for airborne transmission were harmful to the virus it would, on average, slow the accumulation of mutations.

3. Order of acquiring mutations. It is not currently known if the mutations for airborne transmissibility need to be acquired in a specific order. If they do, it would, on average, slow the accumulation of mutations.

"With the information we have, it is impossible to say what the exact risk is of the virus becoming airborne transmissible among humans. However, the results suggest that the remaining three mutations could evolve in a single human host, making a virus evolving in nature a potentially serious threat," said Derek Smith, Professor of Infectious Disease Informatics at the University of Cambridge. "We now know that it is in the realm of possibility that these viruses can evolve in nature, and what needs to be done to assess the risk more accurately of these mutations evolving in nature."

The scientists recommend the following activities be considered high priority for estimating and ameliorating the risk of emergence of aerosol transmissible H5N1 viruses.

First, additional surveillance in regions where viruses with airborne transmission enabling substitutions have been observed and in regions connected to those regions by bird migration and trade. Also, increased surveillance for mutations that might have the same function as those found by the Fouchier and Kawaoka labs.

Second, related to surveillance, some targeted sequencing of H5N1 viruses should be done by "deep sequencing" where the lab sequences many viruses from an individual host to look for viruses that might have accumulated the critical mutations, even if those viruses are just a small proportion of the viruses within an animal.

Third, further investigations are needed to determine which substitutions and combinations of substitutions that are not the same as, but have the same function as, the substitutions identified by the Fouchier and Kawaoka labs are capable of making viruses airborne transmissible between mammals.

Fourth, further studies are needed to elucidate the changes in within-host fitness and between-host transmissibility associated with each airborne transmission enabling substitution and combination of substitutions.

Professor Smith added: "The situation is similar to assessing the risk of an earthquake or tsunami. We don't know exactly when and where, but by increasing monitoring and research -- some of which is already underway -- scientists and public health officials will be able to increase the accuracy with which the risk can be assessed and to minimise those risks."

The research was funded by multiple sources including the European Commission through framework 7 grants EMPERIE and ANTIGONE, the Royal Society, the Human Frontiers Science Program, the Wellcome Trust, and the National Institutes of Health.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by University of Cambridge. The original story is licensed under a Creative Commons license.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

Colin A. Russell, Judith M. Fonville, André E. X. Brown, David F. Burke, David L. Smith, Sarah L. James, Sander Herfst, Sander van Boheemen, Martin Linster, Eefje J. Schrauwen, Leah Katzelnick, Ana Mosterín, Thijs Kuiken, Eileen Maher, Gabriele Neumann, Albert D. M. E. Osterhaus, Yoshihiro Kawaoka, Ron A. M. Fouchier, and Derek J. Smith. The Potential for Respiratory Droplet–Transmissible A/H5N1 Influenza Virus to Evolve in a Mammalian Host. Science, 22 June 2012 DOI: 10.1126/science.1213362

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

H1N1 discovery paves way for universal flu vaccine

May 8, 2012 — University of British Columbia researchers have found a potential way to develop universal flu vaccines and eliminate the need for seasonal flu vaccinations.

Each year, seasonal influenza causes serious illnesses in three to five million people and 200,000 to 500,000 deaths. The 2009 H1N1 pandemic killed more than 14,000 people worldwide. Meanwhile, public health and bioterrorism concerns are heightened by new mutations of the H5N1 "bird flu" virus, published last week by the journal Nature, that could facilitate infection among mammals and humans.

Led by Prof. John Schrader, Canada Research Chair in Immunology and director of UBC's Biomedical Research Centre, the research team found that the 2009 H1N1 "swine flu" vaccine triggers antibodies that protect against many influenza viruses, including the lethal avian H5N1 "bird flu" strain.

Details were recently published in the journal Frontiers in Immunology.

"The flu virus has a protein called hemagglutinin, or HA for short. This protein is like a flower with a head and a stem," says Schrader, a professor in Medicine and Pathology and Laboratory Medicine. "The flu virus binds to human cells via the head of the HA, much like a socket and plug.

"Current flu vaccines target the head of the HA to prevent infections, but because the flu virus mutates very quickly, this part of the HA changes rapidly, hence the need for different vaccines every flu season."

Vaccines contain bits of weak or dead germs that prompt the human immune system to produce antibodies that circulate in the blood to kill those specific germs. However, the research team found that the 2009 pandemic H1N1 vaccine induced broadly protective antibodies capable of fighting different variants of the flu virus.

"This is because, rather than attacking the variable head of the HA, the antibodies attacked the stem of the HA, neutralizing the flu virus," says Schrader. "The stem plays such an integral role in penetrating the cell that it cannot change between different variants of the flu virus."

The new discovery could pave the way to developing universal flu vaccines.

Schrader says the characteristics of the human immune system make it difficult for influenza vaccines to induce broadly protective antibodies against the HA stem. "The pandemic H1N1 swine flu was different, because humans had not been exposed to a similar virus," he adds.

Schrader has evidence that a vaccine based on a mixture of influenza viruses not circulating in humans but in animals should have the same effect and potentially make influenza pandemics and seasonal influenza a thing of the past.

The research team consists of scientists from UBC, the Universities of Ottawa and Toronto, the Ontario Agency for Health Protection and Promotion, the Canadian Food Inspection Agency and the BC Centre for Disease Control. The research was supported by grants from the Canadian Institutes for Health Research, the International Consortium for Anti-Virals and the Michael Smith Foundation for Health Research.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by University of British Columbia.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

C. A. Thomson, Y. Wang, L. M. Jackson, M. Olson, W. Wang, A. Liavonchanka, L. Keleta, V. Silva, S. Diederich, R. B. Jones, J. Gubbay, J. Pasick, M. Petric, François Jean, V. G. Allen, E. G. Brown, J. M. Rini, J. W. Schrader. Pandemic H1N1 Influenza Infection and Vaccination in Humans Induces Cross-Protective Antibodies that Target the Hemagglutinin Stem. Frontiers in Immunology, 2012; 3 DOI: 10.3389/fimmu.2012.00087

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

As flu season approaches, why do college students ignore the H1N1 vaccine?

Oct. 1, 2012 — "Get your flu shot" is advice that many college students ignored in 2009. Findings of a researcher studying the problem highlight the influences of a complex set of interrelated factors, such as students' baseline knowledge, their information seeking, and the credibility of information sources. Students' low response rate is of particular concern because up to November 2009, almost 80 percent of confirmed H1N1 flu cases in the United States occurred in people below age 30.

This fact prompted the Centers for Disease Control and Prevention (CDC) to launch an emergency risk outreach campaign and spurred many college health clinics to offer free vaccine shots. To understand why students ignored the campaign, the researcher surveyed 371 students and discovered that they tended to overestimate how much they knew about the vaccine. Some dubious information about the risks associated with getting the vaccine itself -- not the flu -- were circulated on the social media website youtube.com that complicated efforts to prevent the disease from spreading. Around 30 percent of people in the initial target groups opted in 2009 to receive the vaccine, compared with the 13 percent of the college students sampled in this study.

The research tests a "socio-psychological" approach to how college students process risk information, assessing the role of the complex array of factors related to attitudes and beliefs that shaped students' inaction. The study by University of Buffalo researcher Z. Janet Yang confirms that the approach, the "Risk Information Seeking and Processing" model or RISP, is applicable to public health challenges like choices related to flu vaccination. Her paper, titled "Too Scared or Too Capable? Why Do College Students Stay Away from the H1N1 Vaccine?" appears in the October 2012 issue of Risk Analysis, published by the Society for Risk Analysis.

Because of the high-density living conditions on college campuses, H1N1 spreads rapidly. In 2009, the federal government approved five vaccines, which are readily available and often free to students at their university health clinics, removing those barriers to vaccination. That year, however, "false information about the vaccine's safety was widely spread on social network sites, such as youtube.com, which further contaminated the information environment surrounding H1N1 vaccine" according to Yang. "Even so, the H1N1 influenza was rated as one of the top stories of 2009," citing a major story on the subject in the December 8, 2009, issue of Time Magazine.

Students taking Yang's online survey who deemed the flu vaccine information source as credible sought more information. Getting more information about the vaccine also increased their intention to get the vaccine. This information-seeking response prompted Yang to call on public health experts to design credible health communications with solid information and evidence for support. The researcher says that given the sample size of 317, her results should not be overly generalized or necessarily be applied to all college students.

Yang's study concludes that to promote vaccination and other healthy behaviors in this population may require several changes in health communications approaches. First, studying the target audience's existing perceptions and attitudes to vaccination may help. Second, countering the unwarranted confidence students may have in their knowledge about the flu may be important. Third, illustrating how vaccinations are personally relevant and urgent is critical, as is promoting its social desirability. Yang concludes that an emphasis on the difference between perceived and actual knowledge, studying emotional reactions, improving the accountability of health information and boosting the appeal of receiving a vaccination are critical, particularly as the 2012 flu season starts.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by Society for Risk Analysis (SRA), via Newswise.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

Z. Janet Yang. Too Scared or Too Capable? Why Do College Students Stay Away from the H1N1 Vaccine? Risk Analysis, 2012; DOI: 10.1111/j.1539-6924.2012.01799.x

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

Potential hurdle to universal flu vaccine development may be overcome, study suggests

Aug. 15, 2012 — In the quest for a universal influenza vaccine -- one that elicits broadly neutralizing antibodies that can protect against most or all strains of flu virus -- scientists have faced a sobering question: Does pre-existing immunity generated by prior exposure to influenza virus or vaccine hamper production of broadly neutralizing antibodies? If so, then a universal flu vaccine might work best (and perhaps only) in very young children who have had limited exposure to influenza viruses or vaccines.

Now, in studies using mice and ferrets, investigators from the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have shown that broadly neutralizing influenza antibodies can indeed be elicited by a prime-boost vaccine regimen, even when the animals had pre-existing immunity to influenza.

The vaccine regimen consisted of a DNA vaccine prime followed by boosting with an inactivated seasonal vaccine. It did not matter if the pre-existing immunity was due to exposure to a flu virus or if it followed vaccination with standard seasonal influenza vaccine. Influenza-immune ferrets inoculated with the prime-boost regimen were protected against challenge with unmatched influenza virus strains. If the same effect is found in studies in people, it might be possible to develop vaccines that give long-lasting flu protection to people of all ages, according to the researchers.

Several clinical trials to examine the ability of first-generation universal flu vaccines to generate broadly neutralizing antibodies are either under way or planned at the VRC.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by NIH/National Institute of Allergy and Infectious Diseases.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

C.-J. Wei, H. M. Yassine, P. M. McTamney, J. G. D. Gall, J. R. R. Whittle, J. C. Boyington, G. J. Nabel. Elicitation of Broadly Neutralizing Influenza Antibodies in Animals with Previous Influenza Exposure. Science Translational Medicine, 2012; 4 (147): 147ra114 DOI: 10.1126/scitranslmed.3004273

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

Compound discovered that boosts effect of vaccines against HIV and flu

Aug. 26, 2012 — Oxford University scientists have discovered a compound that greatly boosts the effect of vaccines against viruses like flu, HIV and herpes in mice.

An 'adjuvant' is a substance added to a vaccine to enhance the immune response and offer better protection against infection.

The Oxford University team, along with Swedish and US colleagues, have shown that a type of polymer called polyethyleneimine (PEI) is a potent adjuvant for test vaccines against HIV, flu and herpes when given in mice.

The researchers were part-funded by the UK Medical Research Council and report their findings in the journal Nature Biotechnology.

Mice given a single dose of a flu vaccine including PEI via a nasal droplet were completely protected against a lethal dose of flu. This was a marked improvement over mice given the flu vaccine without an adjuvant or in formulations with other adjuvants.

The Oxford researchers now intend to test the PEI adjuvant in ferrets, a better animal model for studying flu. They also want to understand how long the protection lasts for. It is likely to be a couple of years before a flu vaccine using the adjuvant could be tested in clinical trials in humans, the researchers say.

'Gaining complete protection against flu from just one immunisation is pretty unheard of, even in a study in mice,' says Professor Quentin Sattentau of the Dunn School of Pathology at Oxford University, who led the work. 'This gives us confidence that PEI has the potential to be a potent adjuvant for vaccines against viruses like flu or HIV, though there are many steps ahead if it is ever to be used in humans.'

HIV, flu and herpes are some of the most difficult targets to develop vaccines against. HIV and flu viruses are able to change and evolve to escape immune responses stimulated by vaccines. There aren't any effective vaccines against HIV and herpes as yet, and the flu vaccine needs reformulating each year and doesn't offer complete protection to everyone who receives it. Finding better adjuvants could help in developing more effective vaccines against these diseases.

Most vaccines include an adjuvant. The main ingredient of the vaccine -- whether it is a dead or disabled pathogen, or just a part of the virus or bacteria causing the disease -- primes the body's immune system so it knows what to attack in case of infection. But the adjuvant is needed as well to stimulate this process.

While the need for adjuvants in vaccines has been recognised for nearly 100 years, the way adjuvants work has only recently been understood. The result has been that only a small set of adjuvants is used in current vaccines, often for historical reasons.

The most common adjuvant by far is alum, an aluminium-containing compound that has been given in many different vaccines worldwide for decades. However, alum is not the most potent adjuvant for many vaccine designs.

'There is a need to develop new adjuvants to get the most appropriate immune response from vaccines,' says Professor Sattentau, who is also a James Martin Senior Fellow at the Oxford Martin School, University of Oxford.

The Oxford University team found that PEI, a standard polymer often used in genetic and cell biology, has strong adjuvant activity.

When included in a vaccine with a protein from HIV, flu or herpes virus, mice subsequently mounted a strong immune response against that virus. The immune response was stronger than with other adjuvants that are currently being investigated.

The team also showed that PEI is a potent adjuvant in rabbits, showing the effect is not just specific to mice and could be general.

Another potential advantage of PEI is that it works well as an adjuvant for 'mucosal vaccines'. These vaccines are taken up the nose or in the mouth and absorbed through the mucus-lined tissues there, getting rid of any pain and anxiety from a needle. Mucosal vaccines may also be better in some ways as mucosal tissues are the sites of infection for these diseases (airways for respiratory diseases, genital mucosa for HIV and herpes).

Professor Sattentau suggests that: 'In the best of all possible worlds, you could imagine people would have one dose of flu vaccine that they'd just sniff up their nose or put under their tongue. And that would be it: no injections and they'd be protected from flu for a number of years.

'It's just a vision for the future at the moment, but this promising adjuvant suggests it is a vision that is at least possible.'

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by University of Oxford, via EurekAlert!, a service of AAAS.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

A SMART(er) way to track influenza

June 11, 2012 — Brown University researchers have created a reliable and fast flu-detection test that can be carried in a first-aid kit. The novel prototype device isolates influenza RNA using a combination of magnetics and microfluidics, then amplifies and detects probes bound to the RNA. The technology could lead to real-time tracking of influenza.

Results are published in the Journal of Molecular Diagnostics.

In April 2009, the world took notice as reports surfaced of a virus in Mexico that had mutated from pigs and was being passed from human to human. The H1N1 "swine flu," as the virus was named, circulated worldwide, killing more than 18,000 people, according to the World Health Organization. The Centers for Disease Control and Prevention in the United States said it was the first global pandemic in more than four decades.

Swine flu will not be the last viral mutation to cause a worldwide stir. One way to contain the next outbreak is by administering tests at the infection's source, pinpointing and tracking the pathogen's spread in real time. But such efforts have been stymied by devices that are costly, unwieldy and unreliable. Now, biomedical engineers at Brown University and Memorial Hospital in Rhode Island have developed a biochip that can detect the presence of influenza by zeroing in on the specific RNA sequence and then using tiny magnets in a tube to separate the flu-ridden sequence from the rest of the RNA strand. The result: A reliable, fast prototype of a flu-detection test that potentially can be carried in a first-aid kit and used as easily as an iPhone.

"We wanted to make something simple," said Anubhav Tripathi, associate professor of engineering at Brown and the corresponding author on the paper, published in the Journal of Molecular Diagnostics. "It's a low-cost device for active, on-site detection, whether it's influenza, HIV, or TB (tuberculosis)."

The Brown assay is called SMART, which stands for "A Simple Method for Amplifying RNA Targets." Physically, it is essentially a series of tubes, with bulbs on the ends of each, etched like channels into the biochip.

There are other pathogen-diagnostic detectors, notably the Polymerase Chain Reaction device (which targets DNA) and the Nucleic Acid Sequence Based Amplification (which also targets RNA). The SMART detector is unique in that the engineers use a DNA probe with base letters that match the code in the targeted sequence. This ensures the probe will latch on only to the specific RNA strand being assayed. The team inundates the sample with probes, to ensure that all RNA molecules bind to a probe.

"The device allows us to design probes that are both sensitive and specific," Tripathi said.

This approach creates excess -- that is, probes with no RNA partners. That's OK, because the Brown-led team then attached the probes to 2.8 micron magnetic beads that carry the genetic sequence for the influenza RNA sequence. The engineers then use a magnet to slowly drag the RNA-probe pairs collected in the bulb through a tube that narrows to 50 microns and then deposit the probes at a bulb at the other end. This convergence of magnetism (the magnetized probes and the dragging magnets) and microfluidics (the probes' movement through the narrowing channel and the bulbs) serves to separate the RNA-probe pairs from the surrounding biological debris, allowing clinicians to isolate the influenza strains readily and rapidly for analysis. The team reports that it tracks the RNA-probe beads flawlessly at speeds up to 0.75 millimeters per second.

"When we amplify the probes, we have disease detection," Tripathi said. "If there is no influenza, there will be no probes (at the end bulb). This separation part is crucial."

Once separated, or amplified, the RNA can be analyzed using conventional techniques, such as nucleic acid sequence-based amplification (NASBA).

The chips created in Tripathi's lab are less than two inches across and can fit four tube-and-bulb channels. Tripathi said the chips could be commercially manufactured and made so more channels could be etched on each.

The team is working on separate technologies for biohazard detection.

Stephanie McCalla, who earned her doctorate at Brown last year and is now at the California Institute of Technology, is the first author on the paper. Brown professors of medicine Steven Opal and Andrew Artenstein, with Carmichael Ong and Aartik Sarma, who earned their undergraduate degrees at Brown, are contributing authors.

The U.S. National Institutes of Health and the National Science Foundation funded the research.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by Brown University.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

After epic debate, avian flu research sees light of day

May 2, 2012 — After a marathon debate over a pair of studies that show how the avian H5N1 influenza virus could become transmissible in mammals, and an unprecedented recommendation by a government review panel to block publication, one of the studies was finally and fully published May 3, 2012 in the journal Nature.

Publication caps an epic public conversation that pitted some infectious diseases experts against flu and public health researchers who argued that publication was not only important, but also essential to informing influenza surveillance and preparedness for a virus that could evolve to infect humans and cause a global pandemic.

"Our study shows that relatively few amino acid mutations are sufficient for a virus with an avian H5 hemagglutinin to acquire the ability to transmit in mammals," says Yoshihiro Kawaoka, a University of Wisconsin-Madison flu researcher whose study of H5N1 virus transmissibility was at the center of the debate. "This study has significant public health benefits and contributes to our understanding of this important pathogen. By identifying mutations that facilitate transmission among mammals, those whose job it is to monitor viruses circulating in nature can look for these mutations so measures can be taken to effectively protect human health."

However, Kawaoka cautions there may be other unknown mutations that also enable the virus to transmit in mammals. It is therefore critical, he argues, to continue research to identify additional mutations that have the same effect, and to understand how they work.

The study, conducted by an international team of researchers led by Kawaoka, a UW-Madison professor of pathobiological sciences and a leading expert on influenza, shows that some viruses now circulating in nature require just four mutations to the hemagglutinin protein, which sits on the virus surface and enables it to bind to host cells, to become an even greater threat to human health. A subset of the mutations identified by the Wisconsin group has, in fact, already been detected in some viruses circulating in poultry flocks in Egypt and parts of Southeast Asia, underscoring the urgency of science-based surveillance, Kawaoka says.

In the Nature report, Kawaoka's group describes a laboratory-modified bird flu/human flu hybrid virus that can become transmissible in an animal model for human infection with just a handful of mutations. Because flu viruses in nature are constantly changing as they circulate and easily swap genes with other flu viruses, the possibility of circulating H5N1 viruses hitting the right combination of mutations and becoming a much bigger threat to human health is greater than many experts believed, avers Kawaoka, a faculty member in the UW-Madison School of Veterinary Medicine.

"H5N1 viruses remain a significant threat for humans as a potential pandemic flu strain. We have found that relatively few mutations enable this virus to transmit in mammals. These same mutations have the potential to occur in nature," explains Kawaoka.

Since late 2003, the H5N1 viruses have infected at least 600 humans, mostly in Asia, and killed more than half of the people infected. But the virus, which can be acquired through close contact with domestic fowl, does not easily transmit from human-to-human, a phenomenon that led some scientists to believe H5N1 posed little threat as a potential agent for a global flu pandemic. However, research on transmission of viruses from animal reservoirs was deemed a priority by the United States National Institute of Allergy and Infectious Disease (NIAID) in a 2006 Blue Ribbon Panel report, as well as by the World Health Organization (WHO) in its 2009 Public Health Research Agenda.

In addition to demonstrating transmissibility, Kawaoka's results showed the experimental mutant virus could be controlled by available medical countermeasures. An H5N1 vaccine as well as oseltamivir, an antiviral drug better known by the trade name Tamiflu, both proved effective.

The study was conducted with scientists from the University of Tokyo, where Kawaoka is also on the faculty, Kobe University, and Chubu University.

The flu virus depends on an ability to enter and commandeer host cells to make new virus particles, which go on to infect other cells and spread to other hosts. But flu virus, which typically arises in animal reservoirs such as domestic fowl and pigs before spreading to humans, must adapt by changing its surface topography to match those of a new host species. A protein on the surface of the virus known as hemagglutinin is one of the keys that allow the virus to access host cells. It utilizes a bulb-shaped structure called the "globular head" to bind to host cells at the time of infection. The amino acids in this portion of the hemagglutinin protein are like a combination that opens a locked cell. Without the right combination, the virus is unable to enter a host cell and cause infection.

But flu viruses are masters of shape shifting, a characteristic that helps them adapt to new animal hosts. They readily exchange genetic information and mutate to acquire the molecular features that can make them more infectious.

Whether or not the H5N1 viruses currently circulating in the world can easily acquire the additional mutations needed to cause a pandemic is an open question, according to Kawaoka: "It is hard to predict. The additional mutations may emerge as the virus continues to circulate."

The new work will aid those who monitor flu and could provide a critical early warning. "Should surveillance activities identify flu strains accumulating additional key mutations, these emerging viruses should then be priority candidates for vaccine development and antiviral evaluation," says Kawaoka.

One important upshot of the study by Kawaoka's group is the identification of the mechanism by which the H5N1 virus transmits, a basic discovery that could aid in the development of countermeasures, and that contributes to the store of basic knowledge on influenza virus transmission.

The work will also help governments in some countries justify the significant economic hardship imposed by the mass culling of poultry flocks when potentially dangerous mutations are identified in circulating H5N1 viruses.

The new study was conducted using ferrets, a widely accepted model for influenza research because, when infected with the flu virus, they sneeze and cough, generating small droplets that can carry the virus from one animal to another, demonstrating transmissibility. The ferret respiratory tract also has cellular features similar to those found in humans.

In December 2011, a National Institutes of Health advisory panel, the National Science Advisory Board for Biosecurity (NSABB), recommended redacting critical information from the Kawaoka lab's report, as well as from a similar study conducted in Holland. The unprecedented request was to withhold the methodologies used to make the virus transmissible and to not identify the mutations needed to make the virus transmissible in mammals. This month, the NSABB reversed itself, citing new information and manuscript revisions that more explicitly state the public health rationale for the work as well as the safety and security precautions in place in the labs in Wisconsin and Holland.

It was noted that the virus engineered in Kawaoka's lab was, in fact, of low virulence. The hybrid virus was made by building the H5N1 hemagglutinin gene into the pandemic H1N1 flu virus; the H5-H1N1 hybrid was less pathogenic than pandemic H1N1 virus.

As is the case for all studies of avian influenza transmissibility, the Wisconsin H5N1 work was conducted under strictly controlled conditions with multiple layers of safety and security precautions. Moreover, research involving agents such as highly pathogenic influenza viruses undergoes rigorous federal and institutional oversight including frequent and unannounced inspections. The laboratories such as the one where the new work was conducted are designed to strict specifications and operated to ensure safety.

The animal study of virus infectivity was supported by NIAID, a part of the National Institutes of Health. Other elements of the new study were supported by the Bill & Melinda Gates Foundation, by a Grant-in-Aid for Specially Promoted Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan and by ERATO, the Japan Science and Technology Agency.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by University of Wisconsin-Madison. The original article was written by Terry Devitt.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

Masaki Imai, Tokiko Watanabe, Masato Hatta, Subash C. Das, Makoto Ozawa, Kyoko Shinya, Gongxun Zhong, Anthony Hanson, Hiroaki Katsura, Shinji Watanabe, Chengjun Li, Eiryo Kawakami, Shinya Yamada, Maki Kiso, Yasuo Suzuki, Eileen A. Maher, Gabriele Neumann, Yoshihiro Kawaoka. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature, 2012; DOI: 10.1038/nature10831

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

Pigs may look healthy but can test positive for flu at fairs

Oct. 24, 2012 — More than 80 percent of pigs that tested positive for influenza A virus at Ohio county fairs between 2009 and 2011 showed no signs of illness, according to a new study.

Ohio State University researchers tested 20 pigs each at 53 fair events over those three summers and found at least one flu-positive pig at 12 fairs -- almost a quarter of fairs tested.

The influenza strains identified in pigs in this study include H1N2 and H3N2 viruses -- strains that have been circulating in pigs since 1998. In 2011, all of the H3N2 and H1N2 isolates found in pigs at the fairs contained a gene from the 2009 pandemic strain of H1N1, which is similar to the H3N2v strain causing human illness this year.

Though this finding alone is no cause for panic, it does show how quickly influenza viruses can change, said Andrew Bowman, lead author of the study and a Ph.D. candidate in veterinary preventive medicine at Ohio State.

In a second study led by Bowman, researchers compared the genomic sequences of influenza A viruses recovered in July 2012 from pigs and people. The analysis, showing a greater than 99 percent genetic similarity among the viruses, confirms that pigs and humans were infected with the same virus, indicating interspecies transmission.

As of Sept. 25 this year, the Centers for Disease Control and Prevention (CDC) had confirmed 107 human cases of H3N2v influenza in Ohio since July 2012, with the majority linked to exposure to pigs at agricultural fairs. While most of the human illness caused by H3N2v has been mild, one person, who had a compromised immune system, has died.

The more often that flu viruses are transmitted, the better their chances are of evolving into a strain to which humans are not immune, which is the big-picture concern among scientists monitoring these viral infections.

"Pigs can be infected with human-, avian- and swine-origin influenza viruses, making it possible for these viruses to easily swap their genetic material, which could allow for a new strain to emerge," Bowman said. "The potential is there for newly emerged strains to be the next pandemic we never saw coming."

Bowman and colleagues will continue to investigate strategies to protect swine and public health. In the meantime, the research group has offered potential risk mitigation strategies for fairs with swine competitions to consider: shortening the pig exhibition period, avoiding movement of pigs from one fair to the next, and vaccinating exhibition swine for appropriate influenza A viruses. In addition, the CDC recommends that people with compromised immune systems avoid pig displays at fairs.

Both studies appear online and are scheduled for later print publication. The three-year surveillance at Ohio fairs is published in the journal Emerging Infectious Diseases, and the analysis of human and pig viruses appears in Emerging Microbes & Infections.

Each summer, agricultural fairs bring together animal and human populations that normally don't spend much time in the same place. Pigs are susceptible to multiple strains of influenza A viruses, and the three-year surveillance suggests that the daily visual inspection of pigs at fairs isn't effective at identifying pigs infected with influenza A viruses. This combination of facts adds up to an environment conducive for the transmission of influenza A viruses among pigs and between humans and pigs, potentially in both directions.

"The prevalence of flu in market-weight pigs in commercial swine-production settings is pretty low. But finding flu at the fair shouldn't be that surprising. If you bring 200-plus pigs together from multiple locations and house them with new neighbors for a week in a new environment, they are all bound to share pathogens," Bowman said. "But we were surprised to find as much flu as we did subclinically, when pigs weren't showing any signs of illness."

Bowman and his colleagues, members of the College of Veterinary Medicine's Animal Influenza Ecology and Epidemiology Research Program, tested pigs at 15 Ohio county fairs in 2009, 16 in 2010 and 22 in 2011, using nasal swabs to collect their samples.

The scientists found influenza A virus in at least one pig at 12 (22.6 percent) of the 53 fairs. At the fairs where flu was detected in the pigs, the average frequency of virus detection was 63 percent. Pigs showing signs of illness were observed and tested positive for flu at two fairs, and pigs without signs of illness but positive for flu were found at 10 (18.9 percent) of the 53 fairs. That means pigs at 10 of 12 fairs with positive flu cases, or 83.3 percent of flu-positive pigs, actually didn't appear to be sick. A total of 1,073 pigs were tested over the three-year period.

"This is an explanation of why people were becoming infected in 2012 -- because a high percentage of infected pigs with no clinical symptoms are exhibited at fairs," said Richard Slemons, professor of veterinary preventive medicine at Ohio State and senior author of both studies. "There is potentially high exposure. Therefore, this is something we hadn't seen before or did not know was going on because no one had systematically examined fairs."

Influenza A virus usually infects the respiratory tract, and pigs can "shed" the virus into the air. Slemons described flu-positive swine areas as potentially under a "cloud" of flu particles that would be difficult to avoid. Swine infected with flu typically show clinical signs similar to those in humans: nasal discharge, cough, fever, lethargy and poor appetite.

In the second study, the researchers used swine-origin virus isolates collected during fair surveillance that had continued into the summer of 2012, and obtained the genetic sequences of human-origin influenza A virus isolates from GenBank, the National Institutes of Health genetic sequence database. The human viruses had been recovered from people with flu-like illness following exposure to pigs at an Ohio fair in July 2012.

The timing of the illnesses and the proximity of humans and pigs suggested the viruses were the same, but it was the higher than 99 percent similarity in the viruses' genetic sequences that confirmed interspecies transmission, Bowman said.

"This study presents clear molecular evidence that pigs and humans were concurrently infected with the same strain of influenza A virus at an Ohio county fair in July 2012," he said.

Bowman noted that the results of the two studies create new questions: How do these viruses get to the fair, what can be done to lessen the risk to animals and people, and are the infections going in only one direction, from pigs to humans?

The research program members are continuing to monitor the antigenic and genomic properties of type A influenza viruses in swine.

"It is possible that humans are infecting the pigs. The lineage of the H3N2 strains we see in pigs can be tracked back to the human seasonal flu of the 1990s," Bowman said. "Human-to-swine transmission of influenza viruses has the potential to significantly impact swine health."

He noted that influenza A virus is not considered a food-safety risk as long as pork is cooked properly.

This work was supported by the Centers of Excellence for Influenza Research and Surveillance of the National Institute of Allergy and Infectious Diseases, the Minnesota Center of Excellence for Influenza Research and Surveillance, and the U.S. Department of Agriculture (USDA) Animal and Plant Health Inspection Service's National Veterinary Services Laboratories.

Jacqueline Nolting and Sarah Nelson of Ohio State's Department of Veterinary Preventive Medicine were co-authors on both papers. Additional co-authors of the Emerging Microbes & Infections paper include Srinand Sreevatsan and Carol Cardona of the University of Minnesota, Mary Killian of the USDA and Shannon Page of the Ohio Department of Health.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by Ohio State University.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal References:

Andrew S. Bowman, Jacqueline M. Nolting, Sarah W. Nelson, and Richard D. Slemons. Subclinical Influenza Virus A Infections in Pigs Exhibited at Agricultural Fairs, Ohio, USA, 2009–2011. Emerging Infectious Diseases, 2012 [link]Andrew S Bowman, Srinand Sreevatsan, Mary L Killian, Shannon L Page, Sarah W Nelson, Jacqueline M Nolting, Carol Cardona, Richard D Slemons. Molecular evidence for interspecies transmission of H3N2pM/H3N2v influenza A viruses at an Ohio agricultural fair, July 2012. Emerging Microbes & Infections, 2012; 1 (10): e33 DOI: 10.1038/emi.2012.33

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

New process to make one-way flu vaccine discovered

Dec. 18, 2012 — A new process to make a one-time, universal influenza vaccine has been discovered by a researcher at Georgia State University's Center for Inflammation, Immunity and Infection and his partners.

Associate Professor Sang-Moo Kang and his collaborators have found a way to make the one-time vaccine by using recombinant genetic engineering technology that does not use a seasonal virus.

Instead, the new vaccine uses a virus' small fragment that does not vary among the different strains of flu viruses.

By using the fragment and generating particles mimicking a virus in structure, the immune system can learn to recognize any type of flu virus and attack the pathogen, preventing illness. The research appears in a recent edition of the journal Molecular Therapy, published by the Nature Publishing Group.

"We can now design a vaccine that makes it easier to induce a good immune system response to recognize a pathogen, regardless of how the surface proteins of the virus change," Kang said.

Health officials and scientists must alter flu vaccines every year to match expected strains, and often shortages can result, such as what happened during the 2009 Swine Flu outbreak. A one-time vaccine would prevent such a scenario, Kang said.

"Outbreaks of pandemic can be a dangerous situation, and our current vaccination procedures are not perfect," he said.

Using the new one-time vaccine, using only a fragment rather than the live viral vaccine, such as FluMist, or a killed virus itself, would be safer for people with weakened immune systems, young children and the elderly, Kang said.

The team included researchers from Georgia State, the Emory Vaccine Center at the Emory University School of Medicine, Sungshin Women's University in South Korea and the Animal, Plant and Fisheries Quarantine and Inspection Agency in South Korea.

The research was mainly supported by a grant from the National Institutes of Health and partially supported by the government of South Korea.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by Georgia State University.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

Min-Chul Kim, Jae-Min Song, Eunju O, Young-Man Kwon, Youn-Jeong Lee, Richard W Compans, Sang-Moo Kang. Virus-like Particles Containing Multiple M2 Extracellular Domains Confer Improved Cross-protection Against Various Subtypes of Influenza Virus. Molecular Therapy, 2012; DOI: 10.1038/MT.2012.246

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

More than a quarter of St. Louis EMTs don’t get flu vaccines

Nov. 5, 2012 — Patients are regularly advised by health care professionals to get timely flu shots, but how often do health workers follow what they advocate? A Saint Louis University study reveals that more than 25 percent of St. Louis area Emergency Medical Technicians (EMTs) do not get vaccinated against the flu.

Published in the American Journal of Infection Control, the study indicates that the seasonal influenza vaccine compliance for St. Louis EMTs still remains far below the 90 percent target outlined by the U.S. Department of Health and Human Services' Healthy People 2020 program.

"The Centers for Disease Control and Prevention (CDC) recommends that all health care personnel, including EMTs, receive the seasonal influenza vaccine every year," said Terri Rebmann, Ph.D., associate professor at the Institute for Biosecurity at SLU and co-investigator of the study. "There is a lot of evidence that indicates that vaccinating health care professionals protects workers and patients from influenza-related morbidity and mortality, and reduces sick leave."

The study, funded by the Saint Louis County Department of Health, gauged the seasonal and H1N1 influenza vaccine compliance and whether or not St. Louis EMTs planned to get vaccinated. It also measured the attitudes and beliefs of EMTs about the seasonal influenza vaccine. Sixty percent of EMTs who did not get vaccinated said they do not trust the public health authorities when they say the influenza vaccine is safe, and about a third said that flu vaccine has a lot of side effects and reported being afraid of them. More than half in this group also said they do not believe they can play a role in transmitting influenza to their patients if they are not vaccinated.

"It's a concern that so many EMTs who are educated in health care do not believe that the public health message regarding influenza vaccine safety and efficacy is reliable," said Kate Wright, Ed.D, MPH, associate professor of health management and policy and director of Heartland Centers at SLU, and co-investigator of this study.

Out of 265 St. Louis EMTs who were surveyed for this study, one-fourth said they do not believe that influenza is a serious disease that can cause death. This belief was higher among those who did not get vaccinated.

Influenza causes millions of cases of illness each year, and results in thousands of hospitalizations and deaths, investigators of the study say.

"Non-vaccinated health care personnel have been linked to influenza spread among their patients," Rebmann said. "The seasonal influenza vaccine is safe and effective, with very few side effects -- which are very mild in most individual. Annual vaccination is critical for all health care personnel, including EMTs, to prevent influenza spread in the community."

In order to increase the rate of flu vaccination among EMTs, Rebmann and Wright suggest that health care agencies should implement a mandatory vaccination policy and initiate an education campaign to communicate information about vaccine safety and effectiveness to ETMs.

This study stems from Rebmann and Wright's award-winning flu educational campaign No Flu for You, a collaboration between Saint Louis University School of Public Health and St. Louis County Department of Health. The campaign aims to increase vaccination rates among all groups of health care workers.

"Vaccination is critical," said Rebmann. "Getting vaccinated not only protects the worker, but also his or her patients and family members."

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by Saint Louis University Medical Center.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

Flu antibody’s 'one-handed grab' may boost effort toward universal vaccine, new therapies

Sep. 12, 2012 — Scientists from The Scripps Research Institute and Sea Lane Biotechnologies have solved the co-crystal structure of a human antibody that can neutralize influenza viruses in a unique way. The antibody recognizes the crucial structure that flu viruses use to attach to host cells, even though previously this structure had been thought too small for an antibody to grab effectively. The immune protein manages to hit this precise spot by using just a small part of its target-grabbing apparatus. In so doing, it can neutralize a broad range of dangerous flu viruses.

"This highly focused binding to the receptor binding site using only a single loop on the antibody has never been seen before, and it's really fascinating; it gives us some good ideas about designs for vaccines and therapies," said Ian A. Wilson, the Hansen Professor of Structural Biology at Scripps Research. Wilson was senior investigator of the study along with Ramesh R. Bhatt of Sea Lane Biotechnologies. The report appears online ahead of print on September 16, 2012, in the journal Nature.

The Power of Large Numbers

Sea Lane Biotechnologies, advised by Richard Lerner, the Lita Annenberg Hazen Professor of Immunochemistry at Scripps Research, began by collecting bone marrow from patients who had been exposed to certain key strains of flu. Because the bone marrow is a "fossil record" of all the antibodies a person has ever made, those at Sea Lane felt confident that the antibodies they were looking for would be there. Sea Lane's efforts even went as far as to include advertised appeals on Craigslist for individuals who had certain strains of the flu. Using the internationally and locally collected bone marrow, Sea Lane generated a "comprehensive flu library" of billions of antibodies.

Sea Lane Biotechnologies scientists, led by Bhatt, isolated the unusual new antibody, which they dubbed C05, by screening this enormous library for antibodies that could bind to proteins from a variety of influenza A viruses -- the most dangerous family of flu viruses.

C05 also protected cells in the lab dish from infection by these viruses. In mice, relatively low doses of C05 prevented infections despite influenza A exposures that would have been lethal. The antibody worked as a therapy, too, rescuing 100 percent of mice when administered up to three days after a flu infection had begun.

An Unusual Grip for a Tricky Target

Further tests revealed a curious property of C05. Almost uniquely among broadly neutralizing antibodies against influenza A, it specifically recognizes and blocks the part of the flu virus that mediates viral attachment to host cells. Known as the "receptor binding site" (RBS), this viral site is located on the heads of viral hemagglutinins, spiky structures of sugar and protein that coat the viral envelope.

The RBS is a key functional site on flu viruses and is relatively exposed to the immune system compared to other viral regions. It would be an ideal target for antibodies, except that it is quite small compared to an antibody's usual grip area.

An antibody binds targets using two arm-like structures, each of which has six protein fingers or loops. To get a good grip on the flu RBS with some or all these loops, a typical antibody has to grab not only the RBS, but also some of the surrounding structures in the head, which vary from one flu strain to another. Thus, an antibody that does get a firm grip on this region for one flu strain generally will lose that grip once the strain mutates. "This is why universal flu vaccine strategies in recent years have been focused more on the hemagglutinin stem than on the head," noted Damian C. Ekiert, formerly of Wilson's laboratory at Scripps Research and now of University of California, San Francisco. Ekiert was first author of the paper with Arun K. Kashyap of Sea Lane Biotechnologies.

Wilson's laboratory specializes in the use of X-ray crystallography and other techniques to determine precisely where and how such antibodies bind to their viral targets. Using these methods, his team found that C05 effectively avoids grabbing the hypervariable regions around the flu RBS. Instead it uses a single elongated protein loop to reach in and make a "one-handed" -- or "one-fingered" -- grab of the RBS itself. The antibody apparently works best when two of these active loops, one on each arm, grab two viral RBSs on separate hemagglutinins. "It looks like these antibodies need to cross-link two hemagglutinins to have maximum effect," said Wilson.

Potentially Useful

The RBS has such an important function that it does not change much from strain to strain -- and thus C05 can neutralize a broad range of dangerous influenza A viruses, including H1, H2, H3, and H9 subtypes.

The fact that C05 can make such a precision grab suggests that it and perhaps even more potent antibodies could contribute to antibody-based therapies for severe influenza infections. A universal flu vaccine also might be significantly more effective if it could be designed to elicit such antibodies in people.

"If we can figure out how to induce this sort of antibody in a vaccine, we would have something that's very useful," said Lawrence Horowitz, CEO of Sea Lane Biotechnologies.

In addition to Wilson, Bhatt, Ekiert, Kashyap, and Horowitz, authors of the paper, "Neutralization of Influenza A viruses by insertion of a single antibody loop into the receptor binding site," included Michael A. Dillon, Ryann E. O'Neil, Aleksandr M. Faynboym, and Michael Horowitz of Sea Lane; John Steele and Peter Palese of the Mount Sinai School of Medicine; Adam Rubrum and Richard Webby of St. Jude Children's Research Hospital of Memphis, Tennessee; and Gira Bhabha, Reza Khayat, Jeong Hyun Lee, and Andrew B. Ward of Scripps Research.

The study was funded in part by grants from the National Institutes of Health (P01 AI058113 and GM080209) and the Skaggs Institute for Chemical Biology at Scripps Research.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by The Scripps Research Institute, via AlphaGalileo.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

Damian C. Ekiert, Arun K. Kashyap, John Steel, Adam Rubrum, Gira Bhabha, Reza Khayat, Jeong Hyun Lee, Michael A. Dillon, Ryann E. O’Neil, Aleksandr M. Faynboym, Michael Horowitz, Lawrence Horowitz, Andrew B. Ward, Peter Palese, Richard Webby, Richard A. Lerner, Ramesh R. Bhatt, Ian A. Wilson. Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature, 2012; DOI: 10.1038/nature11414

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

College students report low flu vaccine rate

Dec. 3, 2012 — College football and basketball games may provide more than a way for students to show school spirit -- they could help prevent the flu.

According to a new study by researchers at Wake Forest Baptist Medical Center, colleges and universities should implement new or improved influenza vaccine strategies, such as giving flu shots at sporting events or during campus-wide, day-long campaigns, to increase the number of their students who get the annual flu vaccine.

In the early online edition of the December issue of the Journal of American College Health, the researchers found that only one in five college students at eight North Carolina universities reported getting a flu shot during the 2009-10 flu season.

"Influenza virus is contagious and is known to circulate through college campuses, enhanced by close living quarters, typical social activities and low vaccine coverage," said Kathy Poehling, M.D., associate professor pediatrics at Wake Forest Baptist and lead author of the study.

"With influenza virus already being detected this November, it is likely to increase in the next one to three months and may overlap with exam periods. Although it is hard to predict the severity of the coming flu season, we usually have more influenza activity after a mild season like last year's."

In this study, believed to be the first multi-university study to assess seasonal flu vaccine coverage, a total of 4,090 college students participated in a confidential, web-based survey in late October and November 2009 regarding whether they had received a flu shot.

Overall, 20 percent of the students reported they had been vaccinated during a year in which significant media attention focused on both seasonal and H1N1 flu. The seasonal vaccine coverage varied across the eight universities from 14 percent to 30 percent, which was considerably less than half of the U.S. Department of Health and Human Services' 2020 Healthy People goal of 80 percent coverage for healthy persons 18 to 64 years of age.

In addition, the researchers found that students more often reported receiving the vaccine from a private physician or clinic rather than from student health services, even though it was available free of charge.

Poehling said that the findings of this study, as well as results of previous studies conducted by other institutions, suggest that a multifaceted approach is needed to target students who live both on and off campus. University administrators will need to use a variety of communication approaches and be creative in their outreach efforts to encourage more students to get the annual flu vaccine, she said.

The Wake Forest Baptist study was funded by the Wachovia Research Fund, grant RO1A1079226 from the National Institute of Allergy and Infectious Diseases and grant RO1AA014007 from the National Institute on Alcohol Abuse and Alcoholism.

Co-authors of the study are Jill Blocker, M.S., Edward Ip, Ph.D., Timothy Peters, M.D. and Mark Wolfson, Ph.D., of Wake Forest Baptist.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by Wake Forest Baptist Medical Center.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

Katherine A. Poehling, Jill Blocker, Edward H. Ip, Timothy R. Peters, Mark Wolfson. 2009–2010 Seasonal Influenza Vaccination Coverage Among College Students From 8 Universities in North Carolina. Journal of American College Health, 2012; 60 (8): 541 DOI: 10.1080/07448481.2012.700973

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

Measuring the uncertainties of pandemic influenza

July 2, 2012 — A major collaboration between US research centers has highlighted three factors that could ultimately determine whether an outbreak of influenza becomes a serious epidemic that threatens national health. The research suggests that the numbers in current response plans could be out by a factor of two or more depending on the characteristics of the particular pandemic influenza.

Researchers from Argonne, Los Alamos, and Sandia National Laboratories, and the National Renewable Energy Laboratory, have used sensitivity analysis to uncover the most important disease characteristics pertaining to the spread of infection with an influenza virus. These are: the fraction of the transmission that occurs prior to symptoms, the reproductive number, and the length of each disease stage. Their use of data from past pandemics as well as information on potential viral evolution demonstrates that current response planning may underestimate the pandemic consequences significantly.

"It has become critical to assess the potential range of consequences of a pandemic influenza outbreak given the uncertainty about its disease characteristics while investigating risks and mitigation strategies of vaccines, antiviral drugs, and social distancing measures," explains Jeanne Fair of Los Alamos National Laboratory and her colleagues. The team has used a simulation model and rigorous experimental design with sensitivity analysis to show the extremes of consequences of a potential pandemic outbreak in the USA. The simulation incorporates uncertainty in the evolution and characteristics of the pathogen and differences in the epidemic response, and uncertainties in the sociological response to a pandemic.

Although we are yet to face an H5N1 avian influenza epidemic, the team suggests that they have nevertheless been able to develop a worst-case scenario for all possibilities considering mortality rates and infectiousness based on current knowledge and historical patterns dating back to the 1917-1918 global pandemic. They suggest that a future worst-case influenza pandemic might be up to four times as lethal as the pandemic that occurred towards the end of the Great War. Moreover, their simulation suggests that the use of antiviral drugs may not be as effective as healthcare authorities would hope. On a positive note, they have found that social distancing could be the most effective way to contain the spread of infection, usefully reducing symptoms by an average of 16% although it will cost 50% more than antiviral use through lost working days and commerce.

"Do we prepare for the worst-case scenario when preparing for a pandemic?" asks Fair. "While the worst-case scenario is indeed the worst, it may not be as likely. As far as mortality rates, the 1918 was the worst but really still was only around 2% which is could be considered low." While, the next pandemic could be worse than that of 1917-1918, the worst case scenario may not be as likely, the team concludes. Their study supports earlier findings that no single, pure strategy is best and that a mix of pharmaceutical and non-pharmaceutical interventions will be needed to contain the disease and reduce the total number of deaths. It would be prudent to incorporate these findings in planning for the next pandemic, the team asserts.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by Inderscience Publishers, via EurekAlert!, a service of AAAS.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

Jeanne Fair et al. Measuring the uncertainties of pandemic influenza. Int. J. Risk Assessment and Management, 2012, 16, 1-27

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

Flu vaccine research: Overcoming 'original sin'

Aug. 17, 2012 — Scientists studying flu vaccines have identified ways to overcome an obstacle called "original antigenic sin," which can impair immune responses to new flu strains.

Original antigenic sin (OAS) is a situation where the immune system is fighting with obsolete weapons and has trouble adapting. After encountering one viral strain, and then a new one that is related to the first, the immune system can respond by making antibodies against the first strain, resulting in a less effective defense.

Researchers at Emory Vaccine Center have demonstrated in experiments with mice that OAS can be overcome by using a vaccine additive called an adjuvant, or by repeated immunization with the second viral strain. The results were published this week in Proceedings of the National Academy of Sciences (PNAS).

The first author of the paper is postdoctoral fellow Jin Hyang Kim, who now works on influenza at the Centers for Disease Control and Prevention. The senior author is Joshy Jacob, associate professor of microbiology and immunology at Emory University School of Medicine.

The findings could be important when vaccinating individuals with weaker immune systems, such as people with chronic infections, small children or the elderly, the authors write.

The influenza virus has become so widespread because it can infect a wide range of hosts such as pigs and birds, and because its genome is flexible, Jacob says.

Influenza strains change their DNA in two ways. Antigenic drift occurs as a strain accumulates small mutations, which can help it escape from the host's immune system. Antigenic shift occurs when two strains, possibly from different host species, swap DNA.

"Original antigenic sin is really a reflection of the agility of the influenza virus," he says. "OAS becomes a factor when the new circulating strain is a 'drifted' version of what came before. The old antibodies can't neutralize the new virus, and that helps the new virus survive."

In a Journal of Immunology paper published in 2009, Jin and Jacob showed that OAS could impair the immune responses of mice exposed to two well-studied H1N1 flu strains: PR8, from 1934, and FM1, from 1947.

If mice are immunized first with inactivated PR8 virus and a month later FM1, and then exposed to live FM1, the lungs of the mice had higher viral levels than those that weren't immunized first with PR8. This effect was even stronger after sublethal infection with live virus, rather than vaccination with inactivated virus.

In the new PNAS paper, Jin and colleagues demonstrated that combining the FM1 immunization with an adjuvant allows the mice to respond better to the live virus. The adjuvant is a squalene oil-in-water emulsion. Squalene is a vaccine additive licensed in European countries since the 1990s, but not approved for use in the United States. Surprisingly, the adjuvant could also improve immune responses when combined with the initial PR8 immunization.

"It appears that the adjuvant is making the immune responses to the first viral strain broader, so that a wider range of antibody-producing cells are able to respond to the second strain," Jacob says.

The handicap of the twice-immunized mice against the second virus could also be overcome by a booster shot against the second virus. The authors write:

"Collectively, our findings imply that OAS could potentially be prevented in the naïve human population, especially children, by administering adjuvants with the first influenza vaccine. Alternatively, in the older population with prior influenza virus exposure or vaccinations, original antigenic sin can be minimized by using adjuvants."

The research was supported by the National Institute of Allergy and Infectious Diseases (HHSN266 200700006C).

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by Emory University. The original article was written by Quinn Eastman, Woodruff Health Sciences Center.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

J. H. Kim, W. G. Davis, S. Sambhara, J. Jacob. Strategies to alleviate original antigenic sin responses to influenza viruses. Proceedings of the National Academy of Sciences, 2012; DOI: 10.1073/pnas.0912458109

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

Online self-diagnosis: Am I having a heart attack or is it just the hiccups?

July 16, 2012 — Consumers who self-diagnose are more likely to believe they have a serious illness because they focus on their symptoms rather than the likelihood of a particular disease, according to a new study in the Journal of Consumer Research. This has significant implications for public health professionals as well as consumers.

"In today's wired world, self-diagnosis via internet search is very common. Such symptom-matching exercises may lead consumers to overestimate the likelihood of getting a serious disease because they focus on their symptoms while ignoring the very low likelihood that their symptoms are related to any serious illness," write authors Dengfeng Yan and Jaideep Sengupta (both Hong Kong University of Science and Technology).

Consumers often fear the worst when it comes to their own health while maintaining a calm objectivity with regard to others. For example, when someone else suffers from indigestion, we tend to accurately perceive it as indigestion, but experiencing the same symptom might lead us to panic and worry that we're having a heart attack.

The authors asked consumers to imagine that they or someone else were suffering from common symptoms such as cough, fever, runny nose, and headache. They were then asked to assess the likelihood that they or the other person had contracted either H1N1 (swine flu) or regular flu. Consumers were much more accurate when assessing other people's symptoms. Since they are more likely to misdiagnose themselves, consumers may end up taking unnecessary medical action, which is bad for them, and also bad from a societal cost perspective.

"One of the easiest ways to get rid of this bias is to see a real doctor instead of Dr. Google. A real doctor possesses much more knowledge and will take the prevalence of a disease into consideration because she is viewing the patient from a distance. This will prevent symptoms from exerting a disproportionate influence on the diagnosis," the authors conclude.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by University of Chicago Press Journals, via EurekAlert!, a service of AAAS.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

Dengfeng Yan and Jaideep Sengupta. The Influence of Base Rate and Case Information on Health Risk Perceptions: A Unified Model of Self-Positivity and Self-Negativity. Journal of Consumer Research, February 2013

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

Keeping the flu away: Synthetic protein activates immune system within two hours

July 6, 2012 — San Diego State University researchers at the Donald P. Shiley BioScience Center may have found the secret to helping the immune system fight off the flu before it gets you sick.

A new study published July 6 in the Public Library of Science journal PLoS ONE, finds that EP67, a powerful synthetic protein, is able to activate the innate immune system within just two hours of being administered.

Prior to this study, EP67 had been primarily used as an adjuvant for vaccines, something added to the vaccine to help activate the immune response. But Joy Phillips, Ph.D. a lead author of the study with her colleague Sam Sanderson, Ph.D. at the University of Nebraska Medical Center, saw potential for it to work on its own.

"The flu virus is very sneaky and actively keeps the immune system from detecting it for a few days until you are getting symptoms," Phillips said. "Our research showed that by introducing EP67 into the body within 24 hours of exposure to the flu virus caused the immune system to react almost immediately to the threat, well before your body normally would."

Because EP67 doesn't work on the virus but on the immune system itself, it functions the same no matter the flu strain, unlike the influenza vaccine which has to exactly match the currently circulating strain.

Phillips said while this study focuses on the flu, EP67 has the potential to work on other respiratory diseases and fungal infections and could have huge potential for emergency therapeutics.

"When you find out you've been exposed to the flu, the only treatments available now target the virus directly but they are not reliable and often the virus develops a resistance against them," Phillips said. "EP67 could potentially be a therapeutic that someone would take when they know they've been exposed that would help the body fight off the virus before you get sick."

It could even be used in the event of a new strain of infectious disease, before the actual pathogen has been identified, as in SARS or the 2009 H1N1 influenza outbreak, Phillips said.

Right now, the testing has been done primarily in mice by infecting them with a flu virus. Those that were given a dose of EP67 within 24 hours of the infection didn't get sick (or as sick) as those that were not treated with EP67.

The level of illness in mice is measured by weight loss. Typically, mice lose approximately 20 percent of their weight when they are infected with the flu but mice treated with EP67 lost an average of just six percent. More importantly, mice who were treated a day after being infected with a lethal dose of influenza did not die, Phillips said.

She said there are also huge implications for veterinary applications, since EP67 is active in animals, including birds.

Future research will examine the effect EP67 has in the presence of a number of other pathogens and to look closer at exactly how EP67 functions within different cells in the body.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by San Diego State University.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

Sam D. Sanderson, Marilyn L. Thoman, Kornelia Kis, Elizabeth L. Virts, Edgar B. Herrera, Stephanie Widmann, Homero Sepulveda, Joy A. Phillips. Innate Immune Induction and Influenza Protection Elicited by a Response-Selective Agonist of Human C5a. PLoS ONE, 2012; 7 (7): e40303 DOI: 10.1371/journal.pone.0040303

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

Scientists describe elusive replication machinery of flu viruses

Nov. 21, 2012 — Scientists at The Scripps Research Institute (TSRI) have made a major advance in understanding how flu viruses replicate within infected cells. The researchers used cutting-edge molecular biology and electron-microscopy techniques to "see" one of influenza's essential protein complexes in unprecedented detail. The images generated in the study show flu virus proteins in the act of self-replication, highlighting the virus's vulnerabilities that are sure to be of interest to drug developers.

The report, which appears online in Science Express on November 22, 2012, focuses on influenza's ribonucleoprotein (RNP). RNPs contain the virus's genetic material plus the special enzyme that the virus needs to make copies of itself.

"Structural studies in this area had stalled because of the technical obstacles involved, and so this is a welcome advance," said Ian A. Wilson, the Hansen Professor of Structural Biology at TSRI and senior author of the report with TSRI Professors of Cell Biology Bridget Carragher and Clint Potter. "The data from this study give us a much clearer picture of the flu virus replication machinery."

Unveiling the Mystery of RNPs

At the core of any influenza virus lie eight RNPs, tiny molecular machines that are vital to the virus's ability to survive and spread in its hosts. Each RNP contains a segment -- usually a single protein-coding gene -- of the RNA-based viral genome. This viral RNA segment is coated with protective viral nucleoproteins and has a structure that resembles a twisted loop of chain. The free ends of this twisted loop are held by a flu-virus polymerase enzyme, which handles the two central tasks of viral reproduction: making new viral genomic RNA, and making the RNA gene-transcripts that will become new viral proteins.

Aside from its importance in ordinary infections, the flu polymerase contains some of the key "species barriers" that keep, for example, avian flu viruses from infecting mammals. Mutations at key points on the enzyme have enabled the virus to infect new species in the past. Thus researchers are eager to know the precise details of how the flu polymerase and the rest of the RNP interact.

Getting those details has been a real challenge. One reason is that flu RNPs are complex assemblies that are hard to produce efficiently in the lab. Flu polymerase genes are particularly resistant to being expressed in test cells, and their protein products exist in three separate pieces, or subunits, that have to somehow self-assemble. Until now, the only flu RNPs that have been reproduced in the laboratory are shortened versions whose structures aren't quite the same as those of native flu RNPs. Researchers also are limited in how much virus they can use for such studies.

The team nevertheless managed to develop a test-cell expression system that produced all of the protein and RNA components needed to make full-length flu RNPs. "We were able to get the cells to assemble these components properly so that we had working, self-replicating RNPs," said Robert N. Kirchdoerfer, a first author of the study. Kirchdoerfer was a PhD candidate in the Wilson laboratory during the study, and is now a postdoctoral research associate in the laboratory of TSRI Professor Erica Ollmann Saphire.

Kirchdoerfer eventually purified enough of these flu RNPs for electron microscope analysis at TSRI's Automated Molecular Imaging Group, which is run jointly by Carragher and Potter.

Never Seen Before

The imaging group's innovations enable researchers to analyze molecular samples more easily, in less time, and often with less starting material. "We were able, for example, to automatically collect data for several days in a row, which is unusual in electron microscopy work," said Arne Moeller, a postdoctoral research associate at the imaging group who was the other first author of the study.

Electron microscopes make high-resolution images of their tiny targets by hitting them with electrons rather than photons of light. The images revealed numerous well-defined RNP complexes. To Moeller and his colleagues' surprise, many of these appeared to have new, partial RNPs growing out of them. "They were branching -- this was very exciting," he said.

"Essentially these were snapshots of flu RNPs being replicated, which had never been seen before," said Kirchdoerfer. These and other data, built up from images of tens of thousands of individual RNPs, allowed the team to put together the most complete model yet for flu-RNP structure and functions. The model includes details of how the viral polymerase binds to its RNA, how it accomplishes the tricky task of viral gene transcription, and how a separate copy of the viral polymerase assists in carrying out RNP replication. "We're now able to take a lot of what we knew before about flu virus RNP and map it onto specific parts of the RNP structure," said Kirchdoerfer.

The new flu RNP model highlights some viral weak points. One is a shape-change that a polymerase subunit -- which grabs viral RNA and feeds it to the polymerase's active site on a second subunit -- has to undergo during viral gene transcription. Another is key interaction between the polymerase and viral nucleoproteins. Flu RNPs are long and flexible, curving and bending in electron microscope images; and thus the structural model remains only modestly fine-grained. "You wouldn't be able to design drugs based on this model alone," said Kirchdoerfer, "but we now have a much better idea of how flu RNPs work, and that does suggest some possibilities for better flu drugs."

The study, "Organization of the Influenza Virus Replication Machinery," was funded in part by grants from the National Institutes of Health (AI058113, GM095573) and the Joint Center for Innovation in Membrane Protein Production for Structure Determination (P50GM073197). TSRI's Automated Molecular Imaging Group includes the National Resource for Automated Molecular Microscopy, which is supported by the National Institutes of Health's National Center for Research Resources (2P41RR017573-11) and the National Institute of General Medical Sciences Biomedical Technology Resource Centers (9 P41 GM103310-11).

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by The Scripps Research Institute.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here